Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent
Investigational Drug Radium-223 Chloride Improved Overall Survival By 44 Percent
NKTR-102 Shows 29 Percent Response in Phase II Study
New Two-Step Matching Process Increases Success of Transplants
Weak Electromagnetic Fields Can Possibly Stabilize Tumors
One Flexible Sigmoidoscopy Can Reduce Risk by 31 Percent
Neurocognitive Deficits Affect Future Adult Employment
Smoking, Drinking Factors Affect Adherence to Preventive Regimen
Two Doses of the Vaccine Cervarix Can Be As Effective As Three
HPV-Positive Women Over 30 Should Be Retested Within Two Years
Clinical Trials Approved By NCI CTEP Last Month
Nucynta ER Approved For Managing Chronic Pain In Adults
Zofran Label Change Includes Warnings of QT Prolongation
Agency Approves Two Pairs Of Drugs and Diagnostic Tests
Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL
Trending Stories
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pam Bondi diagnosed with thyroid cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Wafik El-Deiry steps down as director of Brown’s Legorreta Cancer Center
